Early on, a surprising discovery emerged. While CDK2 activity plummeted in the cells upon initial exposure to the drug, within one to two hours, that activity began rebounding. “This was the fastest ...

CDK2 activity in 10 μM dabrafenib‐treated A375 cells. A375 cells expressing DHB‐mCherry were treated with 10 μM dabrafenib at the start of the movie. Two different cell behaviors (escapee and ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build upon safety and tolerability data presented earlier today during a mini ...

Using a rodent model, the researchers showed that doxorubicin increases CDK2 activity in cardiac muscle cells, resulting in cell death. What's more, they demonstrated that suppressing CDK2 levels ...

Using a rodent model, the researchers showed that doxorubicin increases CDK2 activity in cardiac muscle cells, resulting in cell death. What's more, they demonstrated that suppressing CDK2 levels ...

A new study by Washington State University researchers suggests that a protein called CDK2 plays a critical role in heart damage caused by doxorubicin, a commonly used chemotherapy drug.

The dysregulation of CDK activity occurs through overexpression of cyclin E1, a binding partner of CDK2, which is observed in several cancers such as high-grade serous ovarian cancer (HGSOC), bladder ...

Investigators at Incyte Corp. have reported details on the discovery and preclinical characterization of new potent and selective inhibitors of cyclin-dependent kinase 2 (CDK2) as potential anticancer ...

Ensem sees a role for the molecule in the treatment of cancer patients who have acquired resistance to standard of care because of the dysregulation of CDK2 activity. BeiGene is a believer.